GB9307527D0 - New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same - Google Patents

New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same

Info

Publication number
GB9307527D0
GB9307527D0 GB939307527A GB9307527A GB9307527D0 GB 9307527 D0 GB9307527 D0 GB 9307527D0 GB 939307527 A GB939307527 A GB 939307527A GB 9307527 A GB9307527 A GB 9307527A GB 9307527 D0 GB9307527 D0 GB 9307527D0
Authority
GB
United Kingdom
Prior art keywords
hydrogen
processes
lower alkyl
venzamide
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB939307527A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Priority to GB939307527A priority Critical patent/GB9307527D0/en
Publication of GB9307527D0 publication Critical patent/GB9307527D0/en
Priority to US08/220,695 priority patent/US5521170A/en
Priority to IL10922894A priority patent/IL109228A0/xx
Priority to DK94105344T priority patent/DK0620216T3/da
Priority to TW083103003A priority patent/TW260667B/zh
Priority to EP94105344A priority patent/EP0620216B1/en
Priority to PH48055A priority patent/PH30793A/en
Priority to DE69431974T priority patent/DE69431974T2/de
Priority to AT94105344T priority patent/ATE230729T1/de
Priority to ES94105344T priority patent/ES2185635T3/es
Priority to AU59322/94A priority patent/AU679719B2/en
Priority to KR1019940007553A priority patent/KR100290112B1/ko
Priority to CA002121112A priority patent/CA2121112A1/en
Priority to JP6072997A priority patent/JPH072800A/ja
Priority to CN94103577A priority patent/CN1058710C/zh
Priority to HU9401041A priority patent/HUT70197A/hu
Priority to ZA942325A priority patent/ZA942325B/xx
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/20—Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/04—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
GB939307527A 1993-04-13 1993-04-13 New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same Pending GB9307527D0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
GB939307527A GB9307527D0 (en) 1993-04-13 1993-04-13 New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
US08/220,695 US5521170A (en) 1993-04-13 1994-03-31 Benzamide derivatives and pharmaceutical composition comprising the same
IL10922894A IL109228A0 (en) 1993-04-13 1994-04-05 Benzamide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
TW083103003A TW260667B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-04-13 1994-04-07
AT94105344T ATE230729T1 (de) 1993-04-13 1994-04-07 Benzamid-derivate und ihre verwendung als vasopressin-antagonisten
ES94105344T ES2185635T3 (es) 1993-04-13 1994-04-07 Derivados de benzamida y su uso como antagonistas de vasopresina.
EP94105344A EP0620216B1 (en) 1993-04-13 1994-04-07 Benzamide derivatives and their use as vasopressin antagonists
PH48055A PH30793A (en) 1993-04-13 1994-04-07 Benzamide derivatives and pharmaceutical composition comprising the same.
DE69431974T DE69431974T2 (de) 1993-04-13 1994-04-07 Benzamid-Derivate und ihre Verwendung als Vasopressin-Antagonisten
DK94105344T DK0620216T3 (da) 1993-04-13 1994-04-07 Benzamidderivater og deres anvendelse som vasopressinantagonister
AU59322/94A AU679719B2 (en) 1993-04-13 1994-04-08 New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
KR1019940007553A KR100290112B1 (ko) 1993-04-13 1994-04-11 신규한 벤즈아미드 유도체, 그의 제조방법 및 이를 함유하는 약제학적 조성물
HU9401041A HUT70197A (en) 1993-04-13 1994-04-12 New benzamide derivatives, process for producing them and pharmaceutical compositions containing them
CA002121112A CA2121112A1 (en) 1993-04-13 1994-04-12 New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
JP6072997A JPH072800A (ja) 1993-04-13 1994-04-12 ベンズアミド誘導体およびその製造法
CN94103577A CN1058710C (zh) 1993-04-13 1994-04-12 苯甲酰胺衍生物及其制法、用途和含其的药物组合物
ZA942325A ZA942325B (en) 1993-04-13 1994-10-31 New benzamide derivatives processes for the preparation thereof and pharmaceutical composition comprising the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939307527A GB9307527D0 (en) 1993-04-13 1993-04-13 New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same

Publications (1)

Publication Number Publication Date
GB9307527D0 true GB9307527D0 (en) 1993-06-02

Family

ID=10733683

Family Applications (1)

Application Number Title Priority Date Filing Date
GB939307527A Pending GB9307527D0 (en) 1993-04-13 1993-04-13 New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same

Country Status (17)

Country Link
US (1) US5521170A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0620216B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH072800A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100290112B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1058710C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE230729T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU679719B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2121112A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69431974T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0620216T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2185635T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB9307527D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT70197A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL109228A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH30793A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW260667B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA942325B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9408185D0 (en) * 1994-04-25 1994-06-15 Fujisawa Pharmaceutical Co New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
DK1221440T3 (da) 1994-06-15 2007-09-17 Otsuka Pharma Co Ltd Benzoheterocykliske derivater der er nyttige som vasopressin- eller oxytocinmodulatorer
AR002459A1 (es) * 1995-01-17 1998-03-25 American Cyanamid Co Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
US5696112A (en) * 1995-01-17 1997-12-09 American Cyanamid Company Fused heterocyclic azepines as vasopressin antagonists
US5532235A (en) * 1995-01-17 1996-07-02 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5536718A (en) * 1995-01-17 1996-07-16 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5521173A (en) * 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
US5849735A (en) * 1995-01-17 1998-12-15 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5700796A (en) * 1995-01-17 1997-12-23 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5753648A (en) * 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9508637D0 (en) * 1995-04-28 1995-06-14 Fujisawa Pharmaceutical Co New use
GB9511694D0 (en) * 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
TW359669B (en) * 1995-12-15 1999-06-01 Otsuka Pharma Co Ltd Benzazepine derivatives
US5756497A (en) * 1996-03-01 1998-05-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5880122A (en) * 1996-11-01 1999-03-09 American Home Products Corporation 3-Carboxamide derivatives of 5H-pyrrolo 2,1-c! 1,4!-benzodiazepines
AUPO395396A0 (en) 1996-12-02 1997-01-02 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
AUPP150098A0 (en) * 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
US20060025388A1 (en) * 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
DK1143946T3 (da) 1999-04-30 2004-06-07 Univ Michigan Anvendelse af benzodiazepiner til behandling af autoimmune sygdomme induceret af apoptose
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7572788B2 (en) * 1999-04-30 2009-08-11 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US6765004B1 (en) * 1999-06-17 2004-07-20 Ortho-Mcneil Pharmaceutical, Inc. Indoloazepines as vasopressin receptor antagonists
EP1202989A1 (en) * 1999-06-28 2002-05-08 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
US6531495B1 (en) * 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
DE19947457A1 (de) * 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
GB0000079D0 (en) 2000-01-05 2000-02-23 Ferring Bv Novel antidiuretic agents
WO2001082913A2 (en) * 2000-05-03 2001-11-08 Sucampo Ag Use of benzamide derivatives for the treatment of high ocular tension and glaucoma
EP1195166B1 (en) * 2000-10-04 2007-07-25 Astellas Pharma Inc. Use of a vasopressin antagonist such as conivaptan in the manufacture of a medicament for treating pulmonary hypertension
DE10060807A1 (de) * 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US7202239B2 (en) 2001-04-12 2007-04-10 Wyeth Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists
US6977254B2 (en) 2001-04-12 2005-12-20 Wyeth Hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
US7064120B2 (en) 2001-04-12 2006-06-20 Wyeth Tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
US6900200B2 (en) 2001-04-12 2005-05-31 Wyeth Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
US7109193B2 (en) 2001-04-12 2006-09-19 Wyeth Tricyclic diazepines tocolytic oxytocin receptor antagonists
US7022699B2 (en) 2001-04-12 2006-04-04 Wyeth Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
US7326700B2 (en) 2001-04-12 2008-02-05 Wyeth Cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
CN1943786A (zh) * 2002-02-28 2007-04-11 日本烟草产业株式会社 酯化合物及其医药用途
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
US7351709B2 (en) 2004-06-09 2008-04-01 Wyeth Estrogen receptor ligands
EP1632494A1 (en) 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
WO2006040527A1 (en) 2004-10-16 2006-04-20 Astrazeneca Ab Process for making phenoxy benzamide compounds
US8101774B2 (en) * 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
JP3988832B2 (ja) * 2004-11-29 2007-10-10 日本たばこ産業株式会社 窒素含有縮合環化合物及びその用途
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
JP2008528448A (ja) * 2005-01-03 2008-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 新規化合物に関連する組成物および方法、ならびにその標的
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
JP2008545757A (ja) 2005-06-01 2008-12-18 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 溶媒和されていないベンゾジアゼピン組成物および方法
BRPI0613570B8 (pt) 2005-07-09 2021-05-25 Astrazeneca Ab composto, composição farmacêutica e uso de um composto ou um sal farmaceuticamente aceitável do mesmo
DE602006019882D1 (de) * 2005-09-02 2011-03-10 Otsuka Pharma Co Ltd Verfahren für die zubereitung von benzazepinverbindungen oder salzen daraus
US20070105844A1 (en) * 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
CA2628193C (en) 2005-11-01 2012-08-14 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
US7759338B2 (en) * 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
US20080064871A1 (en) * 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds
US20080305169A1 (en) * 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
JP4108729B2 (ja) * 2006-05-26 2008-06-25 日本たばこ産業株式会社 窒素含有縮合環化合物含有医薬組成物
WO2007146167A1 (en) 2006-06-09 2007-12-21 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
CL2007003061A1 (es) 2006-10-26 2008-08-01 Astrazeneca Ab Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
AR064625A1 (es) 2006-12-21 2009-04-15 Astrazeneca Ab Forma cristalina de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-[(1-metiletil)oxi]-n-1h-pirazol-3-ilbenzamida
EP2139331B1 (en) 2007-03-09 2013-02-20 The Regents of the University of Michigan Compositions and methods relating to novel compounds and targets thereof
ES2601856T3 (es) 2007-06-08 2017-02-16 Mannkind Corporation Inhibidores de la IRE-1A
CN101855203B (zh) 2007-09-14 2014-03-19 密执安州立大学董事会 F1f0-atp合成酶抑制剂以及相关的方法
US8188072B2 (en) 2007-11-06 2012-05-29 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
JP5305704B2 (ja) * 2008-03-24 2013-10-02 富士フイルム株式会社 新規化合物、光重合性組成物、カラーフィルタ用光重合性組成物、カラーフィルタ、及びその製造方法、固体撮像素子、並びに、平版印刷版原版
CA2732165A1 (en) 2008-08-04 2010-02-11 Astrazeneca Ab Therapeutic agents 414
US8497307B2 (en) 2008-09-11 2013-07-30 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
WO2010116176A1 (en) * 2009-04-09 2010-10-14 Astrazeneca Ab Pyrazolo [4, 5-e] pyrimidine derivative and its use to treat diabetes and obesity
WO2010116177A1 (en) 2009-04-09 2010-10-14 Astrazeneca Ab A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity
US8604023B2 (en) 2009-04-17 2013-12-10 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
US9056833B2 (en) * 2009-06-03 2015-06-16 Sanofi-Aventis Deutschland Gmbh Crystalline phases of 2′-{[2-(4-methoxy-phenyl)-acetylamino]-methyl}-biphenyl-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide
JP2013505258A (ja) 2009-09-18 2013-02-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ベンゾジアゼピノン化合物およびそれを使用する治療方法
WO2011058193A1 (en) * 2009-11-16 2011-05-19 Mellitech [1,5]-diazocin derivatives
EP2501387B1 (en) 2009-11-17 2016-07-27 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
ES2703752T3 (es) 2009-11-17 2019-03-12 Univ Michigan Regents 1,4-Benzodiazepina-2,5-dionas y compuestos relacionados que presentan propiedades terapéuticas
FR2969605A1 (fr) * 2010-12-28 2012-06-29 Univ Strasbourg Derives de 2,3,4,5-tetrahydro-1h-benzo[b]azepine et leur utilisation
JP2014518853A (ja) * 2011-04-28 2014-08-07 ブリストル−マイヤーズ スクイブ カンパニー 新規な二環式窒素含有ヘテロアリールｔｇｒ５受容体調節因子
CN106029076B (zh) 2013-11-18 2019-06-07 福马疗法公司 作为bet溴域抑制剂的苯并哌嗪组合物
TWI742513B (zh) 2013-11-18 2021-10-11 美商弗瑪治療公司 作為bet溴域抑制劑之四氫喹啉組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2905909B2 (ja) * 1991-04-19 1999-06-14 大塚製薬株式会社 バソプレシン拮抗剤
ES2089033T3 (es) * 1989-10-20 1996-10-01 Otsuka Pharma Co Ltd Compuestos benzoheterociclicos.
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
TW198715B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1991-04-19 1993-01-21 Dtsuka Seiyaku Kk
JPH05320135A (ja) * 1992-05-19 1993-12-03 Yamanouchi Pharmaceut Co Ltd テトラヒドロベンズアゼピン誘導体
AU657424B2 (en) * 1992-07-02 1995-03-09 Otsuka Pharmaceutical Co., Ltd. Oxytocin antagonist
JPH06157480A (ja) * 1992-11-30 1994-06-03 Yamanouchi Pharmaceut Co Ltd 新規なベンズアニリド誘導体
AU6219994A (en) * 1993-03-11 1994-09-26 Yamanouchi Pharmaceutical Co., Ltd. Compound with vasopressin antagonism

Also Published As

Publication number Publication date
KR100290112B1 (ko) 2001-05-15
IL109228A0 (en) 1994-07-31
AU679719B2 (en) 1997-07-10
ZA942325B (en) 1995-02-16
HU9401041D0 (en) 1994-08-29
US5521170A (en) 1996-05-28
ATE230729T1 (de) 2003-01-15
EP0620216B1 (en) 2003-01-08
JPH072800A (ja) 1995-01-06
CN1098406A (zh) 1995-02-08
TW260667B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1995-10-21
CA2121112A1 (en) 1994-10-14
EP0620216A1 (en) 1994-10-19
AU5932294A (en) 1994-10-20
ES2185635T3 (es) 2003-05-01
DK0620216T3 (da) 2003-05-05
DE69431974D1 (de) 2003-02-13
PH30793A (en) 1997-10-17
HUT70197A (en) 1995-09-28
DE69431974T2 (de) 2003-05-22
CN1058710C (zh) 2000-11-22

Similar Documents

Publication Publication Date Title
GB9307527D0 (en) New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
IL107426A0 (en) Heterocyclic compounds, processes for the preparation thereof, and pharmaceutical compositions containing the same
ES2082805T3 (es) Derivados de tiazol, procedimientos para su produccion y composiciones farmaceuticas que comprenden los mismos.
ES8300112A1 (es) Un procedimiento para preparar compuestos de cefem .
ES2137169T3 (es) Nuevos derivados de tiazolilbenzofurano, procedimientos para su preparacion y composicion farmaceutica que los contiene.
GR3017100T3 (en) Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same.
IL92730A0 (en) 2-aminopyrimidinone derivatives,their preparation and pharmaceutical compositions containing them
HUT43051A (en) Process for preparing pyridine-carboxylic acid derivatives and pharmaceutical compositions containing thereof as active ingredients
HU895226D0 (en) Process for the preparation of novel imidazoline derivatives and pharmaceutical compositions containing said compounds as active ingredients
IL86462A0 (en) Alkanesulfonanilide derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
IL90424A (en) Cephem derivatives, processes for the preparation thereof and pharmaceutical composition containing the same
IL103826A0 (en) Thiazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
DE3465594D1 (en) Tropone derivatives, processes for preparation thereof and pharmaceutical composition comprising the same